125I放射性粒子永久植入治疗前列腺癌

目的探讨^125I放射性粒子永久植入治疗前列腺癌的疗效、适应证和并发症。方法应用Prowess2．42治疗计划系统经直肠超声引导，^125I放射性粒子植入治疗前列腺癌患者5例，临床分期T2b 4例，T3 1例。Gleason评分7分3例，6分1例，9分1例。术前PSA5．3～8．7ng／ml。结果治疗后随访12—18个月。5例患者PSA明显下降，12个月后均低于0．5ng／ml；术后3个月开始前列腺体积缩小；术后短期出现不同程度的尿路刺激症状，IPSS评分上升，尿流率下降，但3个月后逐渐好转。患者未出现血尿、血便、直肠溃疡等严重并发症。结论^126I放射性粒子永久植入适用于临床局限性前列腺癌，疗效好，并发症少，并有较好的放射安全性。

Permanent interstitial brachytherapy for localized prostate cancer

Objective To evaluate the indications,complications and efficacy of permanent interstitial brachytherapy in the treatment of clinically localized prostate cancer. Methods Five patients (mean age,73 years;range,59~84 years) with clinically localized stage T 2b to T 3 adenocarcinoma of the prostate were treated with iodine-125 brachytherapy using the transrectal ultrasound guided transperineal implantation technique and Prowess 2.42 treatment planning system.The follow-up period ranged from 12 to 18 months. Results After implantation,the PSA levels of the 5 patients were decreased significantly and were all less than 0.5 ng/ml at 12th post-implant month;and the prostate volume shrunk from the third month. In the early period after the implantation all the patients complained of some voiding problems and had a noticed increase of International Prostate Symptom Score (IPSS),with the decrease of urinary flow rate.But the conditions improved gradually from the third month. No serious complications such as hematuria, bloody stool and rectal ulcer were found in this group. Conclusions Permanent interstitial brachytherapy has better efficacy,fewer complications and more radiation safety in the treatment of clinically localized prostate cancer.